Patrys (PAB.AX) Aandeel Koers

Patrys Ltd is a biotechnology company founded in 2006 and headquartered in Melbourne, Australia. The company focuses on the development of novel antibodies for the treatment of cancer. Patrys Ltd has a strong research and development pipeline, aiming to create innovative and targeted therapies to address unmet medical needs in oncology. With a diverse portfolio of intellectual property, Patrys Ltd has achieved significant milestones and collaborations with leading industry partners. The company is dedicated to advancing its cutting-edge technologies and bringing new and effective cancer treatments to patients worldwide.

The business model of Patrys Ltd is focused on developing and commercializing innovative cancer therapies. Patrys is a biotechnology company that specializes in the development of antibodies for the treatment of cancer and other diseases. The company's key focus is on advancing its proprietary platform technology, PAT-SMART™, which aims to create novel therapies targeting a range of cancers. Patrys collaborates with leading research institutions and experts to develop and test its drug candidates. Through its business model centered around research and development, Patrys aims to bring novel therapies to market that have the potential to improve patient outcomes in the field of oncology.

Patrys Ltd is primarily active in the biotechnology industry.

Patrys Ltd has achieved several significant milestones in its history. Firstly, the company successfully completed its initial public offering (IPO) and got listed on the stock exchange, which allowed it to raise capital for growth and expansion. Additionally, Patrys Ltd has made remarkable breakthroughs in its research and development activities, leading to the development of innovative and potentially impactful therapies. This includes the advancement of its lead drug candidate, PAT-DX1, which has shown promising results in preclinical studies. Furthermore, Patrys Ltd has established strategic collaborations with renowned research institutions and pharmaceutical companies, further validating its scientific expertise and creating potential opportunities for future success.

Patrys Ltd is primarily present in Australia.

Patrys Ltd represents values and a corporate philosophy centered around innovation, collaboration, and commitment to improving patients' lives. The company fosters a culture of scientific excellence, aiming to develop breakthrough antibody therapies for cancer treatment. Patrys Ltd is driven by a patient-centric approach, striving to make a meaningful difference in cancer patients' outcomes through novel and targeted solutions. With a strong focus on research and development, Patrys Ltd is dedicated to advancing the field of oncology and delivering innovative therapies to address unmet medical needs. This commitment underscores Patrys Ltd's passion for improving the lives of cancer patients worldwide.

Omgezet tegen de huidige wisselkoers noteert het aandeel Patrys op 0,02 EUR (0,03 AUD).

Het aandeel Patrys (PAB.AX) is genoteerd aan 1 beurzen, waaronder: ASX (PAB.AX).

Patrys Ltd is a biopharmaceutical company specializing in the discovery, development, and commercialization of antibodies against cancer and other diseases. Founded in 2000, the company is headquartered in Australia and has offices in the USA and Europe. Patrys' business model includes multiple divisions focused on product development and commercialization in various areas. The first division of Patrys focuses on the research and development of antibodies against cancer. The company utilizes its patented technologies to discover novel antibodies specifically targeting cancer cells. These discoveries are then further developed to assess safety and efficacy in clinical trials, with the goal of bringing them to market as new treatment options. Another division of Patrys is the manufacturing and commercialization of antibodies against autoimmune diseases such as Multiple Sclerosis (MS) and rheumatoid arthritis (RA). Patrys' developments in this area aim to identify specific antibodies that inhibit autoimmune reactions without suppressing the immune system overall. The company works closely with leading academics and clinicians to evaluate the efficacy of the developed antibodies and collect extensive clinical data. Thirdly, Patrys has a division for the development of therapeutic antibodies against infectious diseases such as Hepatitis B and C, as well as HIV. The company collaborates closely with scientists and experts in this field to develop antibodies that can directly bind to specific viral proteins and inhibit their spread. In addition to these main divisions, Patrys is also involved in licensing its technologies and know-how to other companies and research institutions. The company has an extensive patent portfolio relating to the discovery of cancer-targeting antibodies and immune-regulatory proteins. These patents are valuable to other biopharmaceutical companies and research institutions pursuing similar developments. Patrys also produces a range of diagnostic products used for the detection and monitoring of cancer and autoimmune diseases. These tests are developed and marketed in collaboration with other companies and institutions. Overall, Patrys' business model is focused on the discovery and development of novel antibodies and biological therapeutics against cancer, autoimmune diseases, and infectious diseases. These developments are valuable both for clinical practice and for licensing to other companies. Patrys aims to continuously expand and optimize its portfolio of diagnostics and therapeutics in collaboration with leading scientists and clinicians.

De omzet van Patrys bedraagt 8.985,00 AUD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.

De winst van Patrys bedraagt -3,41 Miljoen AUD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.

De koers-winstverhouding (P/E) van Patrys bedraagt momenteel -3,01. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Patrys-aandeel in te schatten.

De koers-omzetverhouding (P/S) van Patrys bedraagt momenteel 1.144,67. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Patrys-aandeel.

De Eulerpool Kwaliteitsscore voor Patrys is 3/10.

De ISIN van Patrys is AU000000PAB9. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.

De WKN van Patrys is A0MU4Y. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.

Het tickersymbool van Patrys is PAB.AX. Onder dit beurstickersymbool wordt het Patrys-aandeel op de beurs verhandeld.